Trachoma is estimated to be responsible for 5% of visual impairment and blindness in India.' Certain features of this disease have led to a suggestion that immunological responses may play some part in its pathogenesis. 2 The complement system has a role in defending the host against infection.3 It has been established that activated complement is an important mediator of tissue inflammation. 4 The ocular tissue is known to contain components for both classical and alternate pathway of activation of complement.5 However, very little work is available on serum complements in ocular diseases. In one report it has been found to be altered in acute adenovirus conjunctivitis.6 Here we report observations on the levels of complement components in serum in patients with different stages of trachoma and the effects of medical treatment.
Material and methods
The study was carried out on 56 healthy subjects and 98 patients with trachoma attending the outpatient department of Guru Nanak Eye Centre, New Delhi. The control group comprised healthy subjects who had no evidence of any ocular or systemic disease and who attended the Eye Centre during the same period mainly for the purpose of refraction. The patients with trachoma did not have any other ocular or systemic disease. The age and sex distribution of healthy subjects and the trachoma patients are given in Table 1 . The diagnosis of trachoma was established by detailed clinical examination with the help of a slitlamp biomicroscope and the stages were determined in accordance with MacCallan's classification7 as modified by the World Health Organisation!' The diagnosis of trachoma was further confirmed in the laboratory by Giemsa staining of inclusions in conjunctival scrapings. Only the Giemsa-positive cases were included in this study.
The serum samples were stored at -20°C and assayed within three to four days of collection. They were analysed for Clq, C3, C4, and C5 complement components by a single radial immunodiffusion technique.9 Monospecific goat antisera against human C3, C4, and C5 complement components and their respective reference standards were obtained from Meloy Laboratories, Virginia, USA. Antihuman Clq complement component serum was obtained from Behring Institute, Frankfurt, West Germany. The levels of Clq complement component in the samples of sera were compared with WHO reference standard serum 67/97 and expressed in units/dl, the WHO reference standard being taken as 100 units/dl.
Patients with trachoma stages I, II, and III were treated by oral sulphonamides (sulphamethoxazole 30 mg per kg of body weight daily in divided doses for adults and proportionately less for children according to body weight) for three weeks and topical therapy with tetracycline ointment 1% twice daily for 90 consecutive days. They were followed up once a week to ensure compliance with the treatment. On every visit a thorough clinical examination with the help of a slit-lamp biomicroscope was done. The treatment was considered to be effective when resolu-707 D K Sen, G S Sarin, M Hiranandani, and U K Baveja Table 3 shows the serum Clq, C3, and C4, and C5 complement component levels in patients with trachoma after the resolution of the disease following medical treatment. There was a significant rise in serum Clq complement component level (p<0001) and C3 complement component level (p<0001) in treated patients (stages I+11+III), and the levels almost attained those found in the healthy subjects. However, there was no significant alteration in the serum C4 and C5 complement component levels in these stages. Of the different stages of trachoma, only in stages II and III was there a significant rise in Clq level (p<0001 and p<001 respectively) and C3 level (p<0.01 and p<0.02 respectively); the changes in the level of serum complement components Clq, C3, C4 and C5 in stage I, and C4 and C5 in stages II and III were not statistically significant.
Discussion
The presence of a multiple-system mediating host defence makes the evaluation of the specific role of any single system difficult. This has been particularly true in assessing the role of complement in ocular diseases. In spite of such difficulties it is apparent that complement does have a specific role in the host's defence in man."' The complement system in human serum is able to neutralise or enhance neutralisation of certain viruses in vitro by mechanisms involving both the classical and alternate pathway. II 12 Diseases associated with altered serum complement levels in man have been observed during hepatitis type B, Epstein-Barr virus infection, Argentine haemorrhagic fever, and subacute sclerosing panencephalitis. It has been shown in corneal inflammation that activation of complements by either the classic or the alternate pathway may be involved. 14 15 Clq, C3, and C4 components of complement represent acute-phase reactant in human serum. 16 There was no significant alteration in the levels of C4 and C5 complement components in serum in any of the stages of trachoma. In acute adenovirus conjunctivitis also no significant alterations in C4 and C5 levels in serum have been reported. 6 Clq, C3, and C4 components of complement in serum were normal or increased during the acute phase and normal in the convalescent phase in patients with Epstein-Barr virus infection.2' It has been suggested that complement is important to the patients recovery from viral respiratory tract infection. 22 The observation that the low levels of Clq and C3 complement components became normal when the disease resolved spontaneously, as in stage IV, or after treatment, as in stage II and III, is therefore interesting. 
